Advanced BioNutrition Corp. (ABN), has received a $200,000 award from MdBio
for scaleup and commercialization of ABN's novel microencapsulation technology.
ABN's technology is designed to provide targeted delivery of probiotics and
bioactive compounds to the site of activity in the guts of aquatic animals, using all GRAS (Generally Recognized As Safe) food-grade materials.
Probiotics are 'friendly' bacteria that prevent the growth of pathogenic bacteria and can alleviate the need for antibiotic treatment.
Beneficial bioactive compounds are normally destroyed in the harsh environment of the stomach before they reach the intestines, where they can prevent the growth of pathogenic bacteria. ABN's microencapsulation process protects these helpful bacteria and enables their release to targeted areas of the gastrointestinal tract.
ABN¹s microencapsulation technology provides a revolutionary new method to
deliver easily degraded compounds such as vaccines, enzymes and other nutraceutical products in a bioactive form.
"We are very excited about the potential of this new technology to produce healthier and safer seafood products," said David J. Kyle, president and CEO of ABN. "Our novel microencapsulation technology could also enable the development of a new generation of probiotic products for human consumption."
Work under this project, titled "Commercial Production of Targeted Probiotic MicroCapsules for Aquatic Animals,² will be conducted by ABN at its own laboratories, in conjunction with the Maryland Technology Enterprise Institute at the University of Maryland.
